1. World Health Organization. World malaria report 2020: 20 year of gloval progress &
challenges 2020 [Stand: 17.01.2022]. Verfügbar unter: https://www.who.int/docs/default-
source/malaria/world-malaria-reports/9789240015791-double-page-view.pdf?sfvrsn=2c24349d_5.
2. Suerbaum S, Hahn H, Burchard GD, Kaufmann SHE, Schulz TF, Adler K, Hrsg. Medizinische Mikrobiologie und Infektiologie. 7., überarb. Aufl. Berlin: Springer Medizin; 2012: 881-886.
3. Robert Koch Institut. RKI - RKI-Ratgeber - Malaria; 2015 [Stand: 06.03.2021]. Verfügbar unter:
https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Malaria.html.
4. Redaktion Gesundheitsportal. Malaria; 2018 [Stand: 06.12.2021]. Verfügbar unter:
https://www.gesundheit.gv.at/leben/gesundheitsvorsorge/reisemedizin/infektionskrankheit en/malaria.
5. Centers for Disease Control and Prevention. About Malaria - Where Malaria Occurs; 2020 [Stand: 04.10.2021]. Verfügbar unter:
https://www.cdc.gov/malaria/about/distribution.html#.
6. Pearson RD. Lebenszyklus von Plasmodium. In: MSD-Manual, Ausgabe für medizinische Fachkreise; 2019 [Stand: 30.08.2021]. Verfügbar unter:
https://www.msdmanuals.com/de/profi/infektionskrankheiten/extraintestinale-protozoen/malaria.
7. Antinori S, Galimberti L, Milazzo L, Corbellino M. Biology of human malaria plasmodia including Plasmodium knowlesi. Mediterr J Hematol Infect Dis 2012; 4(1):e2012013. doi:
10.4084/MJHID.2012.013.
8. Hof H, Schlüter D, Dörries R. Medizinische Mikrobiologie. 7. überarbeitete und erweiterte Auflage. Stuttgart: Thieme; 2019: 520-526. (Duale Reihe).
9. Schottelius J. Plasmodium knowlesi: ein neuer Malariaerreger des Menschen. Dtsch Med Wochenschr 2010; (135):297–300. doi: 10.1055/s-0029-1244852.
10. Breman JG. Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children - UpToDate; 2021 [Stand: 01.02.2021]. Verfügbar unter:
https://www.uptodate.com/contents/malaria-clinical-manifestations-and-diagnosis-in-nonpregnant-adults-and-children.
11. Zekar L, Sharman T. Plasmodium Falciparum Malaria. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [Stand: 29.09.2021]. Verfügbar unter:
https://www.ncbi.nlm.nih.gov/books/NBK555962/?report=reader.
12. Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the Era of the Shrinking P. falciparum Map. Trends Parasitol 2020; 36(6):560–70. doi:
10.1016/j.pt.2020.03.009.
13. Mercereau-Puijalon O, Ménard D. Plasmodium vivax and the Duffy antigen: a paradigm revisited. Transfus Clin Biol 2010; 17(3):176–83. doi: 10.1016/j.tracli.2010.06.005.
14. Noedl H. Malariadiagnostik in Theorie und Praxis: a hands-on experience; 2013 [Stand:
17.01.2022]. Verfügbar unter:
https://www.meduniwien.ac.at/hp/fileadmin/tropenmedizin/UW_Noedl/Malariadiagnostik_
Noedl_2013_b.pdf.
15. Okafor CN, Finnigan NA. Plasmodium Ovale Malaria. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [Stand: 20.12.2021]. Verfügbar unter:
https://www.ncbi.nlm.nih.gov/books/NBK519021/.
16. Collins WE, Jeffery GM. Plasmodium malariae: parasite and disease. Clin Microbiol Rev 2007;
20(4):579–92. doi: 10.1128/CMR.00027-07.
17. Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V. Leitlinie:
Diagnostik und Therapie der Malaria 2021 [Stand: 20.12.2021]. Verfügbar unter:
https://www.awmf.org/uploads/tx_szleitlinien/042-001l_S1_Diagnostik-Therapie-Malaria_2021-08.pdf.
18. Kotepui M, Kotepui KU, Milanez GD, Masangkay FR. Global prevalence and mortality of severe Plasmodium malariae infection: a systematic review and meta-analysis. Malar J 2020;
19(1):274. doi: 10.1186/s12936-020-03344-z.
19. Anstey NM, Barber BE, William T. Non-falciparum malaria: Plasmodium knowlesi; 2020 [Stand: 03.11.2021]. Verfügbar unter: https://www.uptodate.com/contents/non-falciparum-malaria-plasmodium-knowlesi.
20. Reiter-Owona I, Thomas L. Labor und Diagnose 2020: Parasitosen: Prof. Lothar Thomas; 2021 [Stand: 09.09.2021]. Verfügbar unter:
https://www.labor-und-diagnose-2020.de/k44.html#_idTextAnchor14470.
21. Milner DA. Malaria Pathogenesis. Cold Spring Harb Perspect Med 2018; 8(1):a025569. doi:
10.1101/cshperspect.a025569.
22. World Health Organization. Guidelines for the treatment of malaria - Third edition; 2015 [Stand: 17.01.2022]. Verfügbar unter: https://www.afro.who.int/sites/default/files/2017-06/9789241549127_eng.pdf.
23. Wilson ME, Weld LH, Boggild A, Keystone JS, Kain KC, Sonnenburg F von et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007;
44(12):1560–8. doi: 10.1086/518173.
24. Baird JK, Price R. Non-falciparum malaria: P. vivax, P. ovale, and P. malariae; 2020 [Stand:
08.02.2021]. Verfügbar unter: https://www.uptodate.com/contents/non-falciparum-malaria-p-vivax-p-ovale-and-p-malariae.
25. Lacerda MVG, Mourão MPG, Coelho HCC, Santos JB. Thrombocytopenia in malaria: who cares? Mem Inst Oswaldo Cruz 2011; 106(1):52–63. doi:
10.1590/S0074-02762011000900007.
26. Seydel KB, Kampondeni SD, Valim C, Potchen MJ, Milner DA, Muwalo FW et al. Brain swelling and death in children with cerebral malaria. N Engl J Med 2015; 372(12):1126–37. doi:
10.1056/NEJMoa1400116.
27. Jakka SR, Veena S, Atmakuri RM, Eisenhut M. Characteristic abnormalities in cerebrospinal fluid biochemistry in children with cerebral malaria compared to viral encephalitis. Fluids Barriers CNS 2006; 3:8. doi: 10.1186/1743-8454-3-8.
28. Lewallen S, Bronzan RN, Beare NA, Harding SP, Molyneux ME, Taylor TE. Using malarial retinopathy to improve the classification of children with cerebral malaria. Trans. R. Soc.
Trop. Med. Hyg. 2008; 102(11):1089–94. doi: 10.1016/j.trstmh.2008.06.014.
29. Yadava SK, Laleker A, Fazili T. Post-malaria neurological syndrome: a rare neurological complication of malaria. Infection 2019; 47(2):183–93. doi: 10.1007/s15010-019-01267-9.
30. Hopkins H. Laboratory tools for diagnosis of malaria; 2020 [Stand: 26.01.2021]. Verfügbar unter: https://www.uptodate.com/contents/laboratory-tools-for-diagnosis-of-malaria.
31. Mundwiler-Pachlatko E, Beck H-P. Maurer's clefts, the enigma of Plasmodium falciparum.
Proc Natl Acad Sci U S A 2013; 110(50):19987–94. doi: 10.1073/pnas.1309247110.
32. Zoller T, Suttorp N. 250e Atlas der Blutausstriche bei Malaria und Babesiose. In: Suttorp N, Möckel M, Siegmund B, Dietel M, Hrsg. Harrisons Innere Medizin. 19. Auflage. Berlin:
McGraw-Hill Education; ABW Wissenschaftsverlag; Thieme; 2016: 250e. Verfügbar unter:
https://eref.thieme.de/cockpits/clHarrison0004/0/coHarrison0004/4-65?context=cockpit&inCockpitLoad=true.
33. Moody A. Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev 2002; 15(1):66–78.
doi: 10.1128/CMR.15.1.66-78.2002.
34. Bell D, Wongsrichanalai C, Barnwell JW. Ensuring quality and access for malaria diagnosis:
how can it be achieved? Nat Rev Microbiol 2006; 4(9 Suppl):S7-20. doi:
10.1038/nrmicro1525.
35. Murray CK, Gasser RA, Magill AJ, Miller RS. Update on rapid diagnostic testing for malaria.
Clin Microbiol Rev 2008; 21(1):97–110. doi: 10.1128/CMR.00035-07.
36. Travassos M, Laufer MK. Antimalarial drugs: An overview; 2021 [Stand: 08.02.2021].
Verfügbar unter: https://www.uptodate.com/contents/antimalarial-drugs-an-overview.
37. Saranphong Y. Quinoline; 2016 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Quinoline_IUPAC.png.
38. Edgar181. 4-aminoquinoline; 2010 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:4-aminoquinoline.svg.
39. Fvasconcellos. Chloroquine; 2006 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Chloroquine.svg.
40. Fitch CD. Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci. 2004; 74(16):1957–72. doi: 10.1016/j.lfs.2003.10.003.
41. Kohlpharma. Fachinformation, Resochina Tabletten 250 mg, Chloroquinphosphat 2016 [Stand: 17.01.2022]. Verfügbar unter: https://s3.eu-central-1.amazonaws.com/prod-cerebro-ifap/media_all/82815.pdf.
42. Nadir SH. Amodiaquin Struktur; 2021 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Amodiaquin_Struktur.svg.
43. Olliaro PL, Mussano P. Amodiaquine for treating malaria. Cochrane Database Syst. Rev. 2003.
doi: 10.1002/14651858.CD000016.
44. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (Internet). Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Abacavir; 2012 [Stand: 17.01.2021]. Verfügbar unter: https://www.ncbi.nlm.nih.gov/books/NBK548225/.
45. Phillips-Howard PA, West LJ. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med 1990; 83(2):82–5. doi:
10.1177/014107689008300208.
46. Edgar181. Piperaquine; 2009 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Piperaquine.png.
47. Davis TME, Hung T-Y, Sim I-K, Karunajeewa HA, Ilett KF. Piperaquine: a resurgent antimalarial drug. Drugs 2005; 65(1):75–87. doi: 10.2165/00003495-200565010-00004.
48. Mysid. Mefloquine structure; 2007 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Mefloquine_structure.svg.
49. Wong W, Bai X-C, Sleebs BE, Triglia T, Brown A, Thompson JK et al. Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis. Nat Microbiol 2017;
2(6):1–17. doi: 10.1038/nmicrobiol.2017.31.
50. Teva Pharmaceuticals USA, Inc. Mefloquine Hydrochloride tablet; 2016 [Stand: 20.12.2021].
Verfügbar unter: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09716a24-d7da-42b2-af29-c03a1b6670bd.
51. Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.
Medikamente gegen Malaria mit reisemedizinischer Bedeutung; 2021 [Stand: 20.12.2021].
Verfügbar unter:
https://dtg.org/index.php?option=com_content&view=article&id=223:medikamente-uebersicht&catid=2.
52. CYL. Quinine; 2011 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Quinine.svg.
53. Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J 2011;
10(1):144. doi: 10.1186/1475-2875-10-144.
54. Cassella-med GmbH & Co. KG. Fachinformation: Limptar, Chininsulfat 2017 [Stand:
17.01.2022]. Verfügbar unter: https://s3.eu-central-1.amazonaws.com/prod-cerebro-ifap/media_all/88096.pdf.
55. Edgar181. 8-aminoquinoline; 2010 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:8-aminoquinoline.svg.
56. Fvasconcellos. Primaquine; 2007 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Primaquine.svg.
57. Freissmuth M, Offermanns S, Böhm S. Pharmakologie & Toxikologie: Von den molekularen Grundlagen zur Pharmakotherapie: mit 129 Tabellen. 1. Aufl. Heidelberg: Springer Medizin;
2012: 710-719.
58. Hill, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am. J. Trop. Med. Hyg. 2006; (75):402–15. Verfügbar unter: https://core.ac.uk/reader/13113091?utm_source=linkout.
59. Fvasconcellos. Tafenoquine; 2007 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Tafenoquine.svg.
60. U.S. Food and Drug Administration. Arakoda tafenoquine tablets; 2018 [Stand: 17.01.2022].
Verfügbar unter:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210607lbl.pdf.
61. Ebstie YA, Abay SM, Tadesse WT, Ejigu DA. Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. DDDT 2016;
10:2387–99. doi: 10.2147/DDDT.S61443.
62. Schlitzer M. Wirk- und Resistenzmechanismen. Medizinische Chemie der Wirkstoffe gegen Malaria. PharmuZ 2009; 38(6):512–20. doi: 10.1002/pauz.200900338.
63. Edgar181. Sulfadoxine; 2008 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Sulfadoxine.png.
64. Fvasconcellos. Pyrimethamine; 2008 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Pyrimethamine.svg.
65. Bzik DJ, Horii, Toshihiro, Inselburg, Joseph. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene: (genomic DNA cloning/gene structure/homology/evolution/malaria parasite). Proc Natl Acad Sci U S A 1987;
(84):8360–4. Verfügbar unter: https://www.pnas.org/content/pnas/84/23/8360.full.pdf.
66. Schönfeld M. Dissertation: Molekulare Surveillance der Medikamentenresistenz von
Plasmodium falciparum anhand von Isolaten aus Tansania [Dissertation]. München: r Ludwig-Maximilians -Universität; 2008.
67. Tropeninstitut. Schutz vor Malaria: Medikamentöse Prophylaxe gegen Malaria; 2017 [Stand:
02.11.2021]. Verfügbar unter: https://tropeninstitut.de/malaria/schutz-vor-malaria/medikamentoese-prophylaxe-gegen-malaria#Sulfadoxin.
68. World Health Organization. Addition of sulfadoxine-pyrimethamine for Intermittent
Preventive Treatment in pregnancy in the WHO Model List of Essential Medicines for adults 2018 [Stand: 17.01.2022]. Verfügbar unter:
https://www.who.int/selection_medicines/committees/expert/22/applications/s6.5.3.2_sulf adoxine-pyrimethamine_IPTp.pdf.
69. Mysid. Atovaquone structure; 2007 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Atovaquone_structure.svg.
70. Fvasconcellos. Proguanil; 2007 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Proguanil.svg.
71. Kohlpharma. Malarone Filmtabletten 250 mg/100 mg, Fachinformation 2015 [Stand:
17.01.2022]. Verfügbar unter: https://s3.eu-central-1.amazonaws.com/prod-cerebro-ifap/media_all/78642.pdf.
72. Gaillard T, Madamet M, Tsombeng FF, Dormoi J, Pradines B. Antibiotics in malaria therapy:
which antibiotics except tetracyclines and macrolides may be used against malaria? Malar J 2016; 15(1):556. Verfügbar unter:
https://malariajournal.biomedcentral.com/articles/10.1186/s12936-016-1613-y.
73. Neurotiker. Tetracycline; 2007 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Tetracycline.svg.
74. May DB. Tetracyclines; 2021 [Stand: 10.10.2021]. Verfügbar unter:
https://www.uptodate.com/contents/tetracyclines.
75. McFadden GI. Apicoplast 2014; 24(7):R262-3 [Stand: 17.01.2022]. Verfügbar unter:
https://www.cell.com/current-biology/pdf/S0960-9822(14)00025-6.pdf.
76. Gaillard T, Madamet M, Pradines B. Tetracyclines in malaria. Malar J 2015; 14(1):445.
Verfügbar unter: https://malariajournal.biomedcentral.com/articles/10.1186/s12936-015-0980-0#ref-CR36.
77. Wiedermann-Schmidt U, Kollaritsch H, Beubler E, Haditsch M, Hatz C, Jeschko E-M et al.
Malariaprophylaxe. ÖAZ 2011:110–30. Verfügbar unter:
https://www.meduniwien.ac.at/hp/fileadmin/tropenmedizin/DokumenteChristina/CSMalaria prophylaxe_lit2.pdf.
78. Mitcheltree M. Clindamycin; 2017 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Clindamycin_1.png.
79. Mižoch L. Artemisinin; 2006 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Artemisinin.svg.
80. Charlesy. Artemether; 2014 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Artemether.svg.
81. En:user:catclock. Lumefantrine-; 2013 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Lumefantrine-skeletal.svg.
82. Novartis Pharmaceuticals Corporation. coartem: (artemether and lumefantrine) 2009 [Stand:
20.12.2021]. Verfügbar unter:
https://www.novartis.us/sites/www.novartis.us/files/coartem.pdf.
83. Lexicomp. Artemether and lumefantrine: Drug information - UpToDate; 2021 [Stand:
04.11.2021]. Verfügbar unter:
http://somepomed.org/articulos/contents/mobipreview.htm?11/3/11327?source=HISTORY.
84. Charlesy. Artesunate; 2014 [Stand: 20.12.2021]. Verfügbar unter:
https://commons.wikimedia.org/wiki/File:Artesunate.svg.
85. U.S. Food and Drug Administration. Artesunate for Injection 2020. Verfügbar unter:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf.
86. Ashley EA, Phyo AP. Drugs in Development for Malaria. Drugs 2018; 78(9):861–79. doi:
10.1007/s40265-018-0911-9.
87. Bouwman S, Zoleko-Manego R, Renner KC, Schmitt EK, Mombo-Ngoma G, Grobusch MP. The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound. Travel Med Infect Dis 2020; 36:101765. doi: 10.1016/j.tmaid.2020.101765.
88. Novartis Pharmaceuticals. To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria - Tabular View - ClinicalTrials.gov; 2021 [Stand: 20.12.2021]. Verfügbar unter:
https://clinicaltrials.gov/ct2/show/record/NCT04675931?cond=KAE609&phase=1&draw=2&r ank=5.
89. White NJ, Duong TT, Uthaisin C, Nosten F, Phyo AP, Hanboonkunupakarn B et al. Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. N Engl J Med 2016; 375(12):1152–60. doi:
10.1056/NEJMoa1602250.
90. Novartis Pharmaceuticals, Medicines for Malaria Venture. A Phase 2 Interventional,
Multicenter, Randomized Open Label Study to Determine the Effective and Tolerable Dose of KAF156 and Lumefantrine Solid Dispersion Formulation in Combination, Given Once Daily for
NCT03167242, CKAF156A2202; 2021 [Stand: 05.11.2021]. Verfügbar unter:
https://clinicaltrials.gov/ct2/show/NCT03167242.
91. LaMonte GM, Rocamora F, Marapana DS, Gnädig NF, Ottilie S, Luth MR et al. Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway. Nat Commun 2020; 11(1):1780. Verfügbar unter:
https://www.nature.com/articles/s41467-020-15440-4#Sec1.
92. Adoke Y, Zoleko-Manego R, Ouoba S, Tiono AB, Kaguthi G, Bonzela JE et al. A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and
pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria. Malar J 2021; 20(1):222. doi:
10.1186/s12936-021-03749-4.
93. Toure OA, Mwapasa V, Sagara I, Gaye O, Thompson R, Maheshwar AV et al. Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Randomized, Multicenter Trial in India and Africa. Clin Infect Dis 2017; 65(10):1711–20. doi: 10.1093/cid/cix617.
94. Toure OA, Valecha N, Tshefu AK, Thompson R, Krudsood S, Gaye O et al. A Phase 3, Double-Blind, Randomized Study of Arterolane Maleate-Piperaquine Phosphate vs Artemether-Lumefantrine for Falciparum Malaria in Adolescent and Adult Patients in Asia and Africa. Clin Infect Dis 2016; 62(8):964–71. doi: 10.1093/cid/ciw029.
95. Koita OA, Sangaré L, Miller HD, Sissako A, Coulibaly M, Thompson TA et al. AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. Lancet Infect. Dis. 2017; 17(12):1266–75. doi: 10.1016/S1473-3099(17)30365-1.
96. Nardella F, Mairet-Khedim M, Roesch C, Maher SP, Ke S, Leang R et al. Cross-resistance of the chloroquine-derivative AQ-13 with amodiaquine in Cambodian Plasmodium falciparum isolates. J. Antimicrob. Chemother. 2021; 76(10):2565–8. doi: 10.1093/jac/dkab219.
97. Foy B. Repeat Ivermectin Mass Drug Administrations for MALaria Control II - Tabular View - ClinicalTrials.gov; 2019 [Stand: 05.11.2021]. Verfügbar unter:
https://clinicaltrials.gov/ct2/show/record/NCT03967054?cond=Ivermectin+malaria&draw=2
&rank=1.
98. Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong'o BO, Chen T et al. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with
dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 2018; 18(6):615–26.
doi: 10.1016/S1473-3099(18)30163-4.
99. Dahl EL, Rosenthal PJ. Apicoplast translation, transcription and genome replication: targets for antimalarial antibiotics. Trends Parasitol 2008; 24(6):279–84. doi:
10.1016/j.pt.2008.03.007.
100. Rosenthal PJ. Azithromycin for Malaria? Am. J. Trop. Med. Hyg. 2016; 95(1):2–4. doi:
10.4269/ajtmh.16-0332.
101. Breman JG. Malaria: Epidemiology, prevention, and control; 2021 [Stand: 12.10.2021].
Verfügbar unter: https://www.uptodate.com/contents/malaria-epidemiology-prevention-and-control.
102. Tan KR. Prevention of malaria infection in travelers; 2021 [Stand: 12.10.2021]. Verfügbar unter: https://www.uptodate.com/contents/prevention-of-malaria-infection-in-travelers.
103. Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002; 347(1):13–8. doi: 10.1056/NEJMoa011699.
104. Breisch NL. Prevention of arthropod and insect bites: Repellents and other measures; 2020 [Stand: 20.12.2021]. Verfügbar unter: https://www.uptodate.com/contents/prevention-of-arthropod-and-insect-bites-repellents-and-other-measures.
105. Bohbot JD, Dickens JC. Insect repellents: modulators of mosquito odorant receptor activity.
PLoS ONE 2010; 5(8):e12138. doi: 10.1371/journal.pone.0012138.
106. Walliczek-Dworschak U. Permethrin. Vidal MMI Germany GmbH 2019 [Stand: 07.11.2021].
Verfügbar unter:
https://www.gelbe-liste.de/wirkstoffe/Permethrin_10077#Wirkmechanismus.
107. Centers for Disease Control and Prevention. Malaria Worldwide: How Can Malaria Cases and Deaths Be Reduced? - Vaccines; 2021 [Stand: 23.10.2021]. Verfügbar unter:
https://www.cdc.gov/malaria/malaria_worldwide/reduction/vaccine.html.
108. Malaria Vaccine Funders Group. Malaria Vaccine Technology Roadmap 2013 [Stand:
17.01.2022]. Verfügbar unter:
https://www.malariavaccine.org/sites/mvi/files/content/page/files/TRM_update_nov13.pdf.
109. Metzger WG, Sulyok Z, Theurer A, Köhler C. Entwicklung von Impfstoffen gegen Malaria – aktueller Stand. Bundesgesundheitsbl 2020; 63(1):45–55. doi: 10.1007/s00103-019-03070-1.
110. Nussenzweig RS, Vanderberg GJ, MOST H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 1967; 216(5111):160–2.
doi: 10.1038/216160a0.
111. Zavala F, Tam JP, Hollingdale MR, Cochrane AH, Quakyi I, Nussenzweig RS et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 1985;
228(4706):1436–40. doi: 10.1126/science.2409595.
112. Hill AVS. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci 2011; 366(1579):2806–
14. doi: 10.1098/rstb.2011.0091.
113. World Health Organization. WHO recommends groundbreaking malaria vaccine for children at risk; 2021 [Stand: 27.10.2021]. Verfügbar unter: https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk.
114. Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci Rep 2017; 7:46621. doi:
10.1038/srep46621.
115. Duffy PE, Patrick Gorres J. Malaria vaccines since 2000: progress, priorities, products. npj Vaccines 2020; 5(1):48. doi: 10.1038/s41541-020-0196-3.
116. Clyde DF, MOST H, McCarthy VC, Vanderberg JP. Immunization of man against
sporozite-117. Laurens MB. RTS,S/AS01 vaccine (Mosquirix™): an overview. Hum. Vaccines Immunother.
2020; 16(3):480–9. doi: 10.1080/21645515.2019.1669415.
118. Valéa I, Adjei S, Usuf E, Traore O, Ansong D, Tinto H et al. Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal
conjugate and rotavirus vaccines in African children: A randomized controlled trial. Hum.
Vaccines Immunother. 2018; 14(6):1489–500. doi: 10.1080/21645515.2018.1442996.
119. European Medicines Agency. Mosquirix: Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 2015 [Stand: 17.01.2022]. Verfügbar unter:
https://www.ema.europa.eu/en/documents/outside-eu-summary/mosquirix-medicine-overview_en.pdf.
120. Tinto H. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386(9988):31–45. doi: 10.1016/S0140-6736(15)60721-8.
121. Tinto H, Otieno W, Gesase S, Sorgho H, Otieno L, Liheluka E et al. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Lancet Infect. Dis. 2019;
19(8):821–32. doi: 10.1016/S1473-3099(19)30300-7.
122. Molina-Franky J, Cuy-Chaparro L, Camargo A, Reyes C, Gómez M, Salamanca DR et al.
Plasmodium falciparum pre-erythrocytic stage vaccine development. Malar J 2020; 19(1):56.
doi: 10.1186/s12936-020-3141-z.
123. Murphy SC, Deye GA, Sim BKL, Galbiati S, Kennedy JK, Cohen KW et al. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection. PLoS Pathog 2021; 17(5):e1009594. doi: 10.1371/journal.ppat.1009594.
124. Oneko M, Steinhardt LC, Yego R, Wiegand RE, Swanson PA, Kc N et al. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat Med 2021; 27(9):1636–45. Verfügbar unter: https://www.nature.com/articles/s41591-021-01470-y.
125. Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci.
Transl. Med. 2015; 7(286):286re5. doi: 10.1126/scitranslmed.aaa2373.
126. Tiono AB, Nébié I, Anagnostou N, Coulibaly AS, Bowyer G, Lam E et al. First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. PLoS ONE 2018; 13(12):e0208328. Verfügbar unter:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291132/pdf/pone.0208328.pdf.
127. Graves P, Gelband H. Vaccines for preventing malaria (pre-erythrocytic). Cochrane Database Syst. Rev. 2006; (4):CD006198. doi: 10.1002/14651858.CD006198.
128. Moorthy V, Binka F. R21/Matrix-M: a second malaria vaccine? Lancet 2021;
397(10287):1782–3. doi: 10.1016/S0140-6736(21)01065-5.
129. Datoo MS, Natama MH, Somé A, Traoré O, Rouamba T, Bellamy D et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to
children in Burkina Faso: a randomised controlled trial. Lancet 2021; 397(10287):1809–18.
doi: 10.1016/S0140-6736(21)00943-0.
130. Ferguson DJP, Balaban AE, Patzewitz E-M, Wall RJ, Hopp CS, Poulin B et al. The repeat region of the circumsporozoite protein is critical for sporozoite formation and maturation in
Plasmodium. PLoS ONE 2014; 9(12):e113923. doi: 10.1371/journal.pone.0113923.
131. Carter R. Transmission blocking malaria vaccines. Vaccine 2001; 19(17-19):2309–14. doi:
10.1016/S0264-410X(00)00521-1.
132. Chaturvedi N, Bharti PK, Tiwari A, Singh N. Strategies & recent development of transmission-blocking vaccines against Plasmodium falciparum. Indian J. Med. Res. 2016; 143(6):696–711.
doi: 10.4103/0971-5916.191927.
133. European Vaccine Initiative. MMVC; 2021 [Stand: 25.10.2021]. Verfügbar unter:
https://www.euvaccine.eu/malaria-vaccines/MMVC.
134. Chêne A, Houard S, Nielsen MA, Hundt S, D'Alessio F, Sirima SB et al. Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report. Malar J 2016; 15(1):476. doi: 10.1186/s12936-016-1527-8.
135. CureVac. CureVac entwickelt innovative mRNA-Impfstoffe gegen Influenza und Malaria - CureVac; 2018 [Stand: 25.10.2021]. Verfügbar unter:
https://www.curevac.com/2018/02/18/curevac-entwickelt-innovative-mrna-impfstoffe-gegen-influenza-und-malaria/.
136. Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev. Vaccines 2016; 15(3):313–29. doi: 10.1586/14760584.2016.1124762.
137. World Health Organization. Global technical strategy for malaria 2016–2030, 2021 update
137. World Health Organization. Global technical strategy for malaria 2016–2030, 2021 update